Instrument NameEli Lilly and CompanyInstrument Symbol(LLY-N)

Instrument ExchangeNYSE

The prospects of the latter two companies looked better following the European pharmaceutical's new clinical trial readout.

At a stroke, it's got a product authorized for a specific use in 27 countries.

Eli Lilly stock may look expensive, but that may not be the case in a few years as the business grows at a rapid pace.

Lilly could take a step that's positive for the stock and investors over the long term.

A looming threat from a very powerful rival could significantly dampen a key business for the company.

Terns has a modest market cap of less than $800 million, and its possible upside could be massive.

Most trillion-dollar companies today are in the technology sector, but one particular healthcare stock is knocking on the door of a trillion-dollar valuation.

Telemedicine once seemed like it was going to revolutionize healthcare.

Global Markets Canadian Markets: Canada’s TSX stock rose on a increase in the oil price, while the Trudeau government added new mortgage rules to win over young voters. Air Canada’s pilots agreed to a deal, which saw the company’s stock jump over 3 percent as a result. American  Markets: American...

Getting in on the ground floor sounds like a great idea, but not if the building ends up crumbling.

These stocks are built for the long run.

If you accumulate a large enough balance, you can generate a lot of dividend income without having to target high-yielding, risky investments.

The drug giant's winning ways look set to continue for a while.

Recently revealed trial results for Roche's experimental weight-management drug suggest Viking Therapeutics is on the right track.

The company is looking especially good after some bad news coming from a rival.

Global Markets Canada: The TSX jumped 1 percent, driven largely by a steady rise in oil and gold prices. This move higher in commodity prices bolstered investor confidence and provided a lift to the Canadian stock market. USA: American markets also rose following the release of August’s Consumer Price Index...

Amgen is a decently valued stock that has an excellent business and also gives investors a way to potentially gain exposure to a lucrative weight loss market.

An investment in these players today could score a big win down the road.

The company had a dispiriting update to offer about an investigational drug.

The biotech continued to get attention from both pundits and investors, thanks largely to its investigational obesity drug.

There's a massive reason these stocks should split now.

There's a little appreciated reason to own Eli Lilly stock, and it has nothing to do with its medicines.

Telemedicine was one of the most in-demand services during the height of the COVID-19 pandemic.

Eli Lilly and Regeneron Pharmaceuticals are good stock-split candidates thanks to years of successes.

The executive change comes months after former CFO Anat Ashkenazi stepped down to join Google parent Alphabet